BIOMARIN PHARMACEUTICAL INC (BMRN)
US09061G1013 - Common Stock
| 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 755.13M | 724.50M | 587.30M | 649.20M | 437.40M | |||
| Marketable Securities | 318.68M | 567.00M | 426.60M | 416.20M | 316.40M | |||
| Receivables | 633.70M | 461.30M | 373.40M | 448.40M | 377.40M | |||
| Inventories | 1.11B | 894.10M | 776.70M | 698.50M | 680.30M | |||
| Other Current Assets | 141.39M | 104.50M | 110.40M | 129.90M | 130.70M | |||
| Total Current Assets | 2.96B | 2.75B | 2.27B | 2.34B | 1.94B | |||
| Non-Current Assets | ||||||||
| PPE Net | 1.11B | 1.11B | 1.08B | 1.09B | 1.07B | |||
| Investments And Advances | 622.43M | 333.80M | 507.80M | 285.50M | 412.00M | |||
| Goodwill | 196.20M | 196.20M | 196.20M | 196.20M | 197.00M | |||
| Intangibles | 294.70M | 338.60M | 388.70M | 417.30M | 456.60M | |||
| Other Non-Current Assets | 1.66B | 1.64B | 1.55B | 1.52B | 612.00M | |||
| Total Non-Current Assets | 3.89B | 3.62B | 3.73B | 3.51B | 2.75B | |||
| TOTAL ASSETS | 6.84B | 6.38B | 6.00B | 5.85B | 4.69B | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | 494.02M | 2.30M | 2.30M | 2.90M | 365.10M | |||
| Accrued Expenses | 322.84M | 317.80M | 277.10M | 266.30M | 287.90M | |||
| Accounts Payable | 315.51M | 231.20M | 193.00M | 191.40M | 241.00M | |||
| Other Current Liabilities | 44.66M | 37.50M | 67.50M | 32.00M | 38.50M | |||
| Total Current Liabilities | 1.18B | 588.90M | 539.80M | 492.50M | 932.50M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 593.17M | 1.08B | 1.08B | 1.08B | 492.90M | |||
| Deferred Taxes/Income | N/A | N/A | N/A | N/A | N/A | |||
| Other Non-Current Liabilities | 119.86M | 99.80M | 111.70M | 170.30M | 142.20M | |||
| Total Non-Current Liabilities | 713.03M | 1.18B | 1.19B | 1.25B | 635.20M | |||
| TOTAL LIABILITIES | 1.89B | 1.77B | 1.73B | 1.74B | 1.57B | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -621.55M | -789.20M | -925.70M | -861.60M | -1.72B | |||
| Additional Paid In Capital | 5.61B | 5.40B | 5.19B | 4.99B | 4.83B | |||
| Common Shares | 189.00K | 200.00K | 200.00K | 200.00K | 200.00K | |||
| Other Shareholders' Equity | -39.52M | -600.00K | 6.10M | -29.90M | 6.60M | |||
| Shares Outstanding | 188.60M | 186.30M | 183.90M | 181.70M | 179.80M | |||
| Tangible Book Value per Share | 23.65 | 21.84 | 20.04 | 19.22 | 13.73 | |||
| Total Shareholders' Equity | 4.95B | 4.60B | 4.27B | 4.11B | 3.12B | |||
| TOTAL LIABILITIES AND EQUITY | 6.84B | 6.38B | 6.00B | 5.85B | 4.69B | |||
| Statistics | ||||||||
| Debt/Equity | 0.12 | 0.24 | 0.25 | 0.26 | 0.16 | |||
| Current Ratio | 2.51 | 4.67 | 4.21 | 4.76 | 2.08 | |||
| Return On Assets (ROA) | 2.45% | 2.22% | -1.07% | 14.69% | -0.51% | |||
| Return On Equity (ROE) | 3.39% | 3.08% | -1.50% | 20.92% | -0.76% | |||
| Return On Invested Capital (ROIC) | 2.20% | 0.88% | N/A | N/A | N/A | |||
| Return On Invested Capital Ex Cash (ROICexc) | 2.72% | 1.14% | N/A | N/A | N/A | |||
| Return On Invested Capital Ex Cash + Goodwill (ROICexcg) | 3.05% | 1.29% | N/A | N/A | N/A | |||
All data in USD